Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport

Journal of Pharmaceutical Sciences

Volumn 92, Issue 10, 2003, Pages 1968-1980

  Tolle Sander, Sanna ^a   Grill, Andreas ^b   Joshi, Hemant ^c,d   Kapil, Ram ^c   Persiani, Stefano ^d   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Rotta Research Laboratorium   (Italy)

^d Barr Laboratories   (United States)

Author keywords

Absorption; Active transport; Bioavailability; Dexloxiglumide; MRP1; P glycoprotein; Permeability

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DEXLOXIGLUMIDE; FLUORESCEIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; CELL POLARITY; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PH; PHARMACEUTICS;

EID: 0141507964     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10428     Document Type: Article

References (37)

1. Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175(3):880-885.
2. Curatolo W. 1998. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm Sci Technol Today 1:387.
3. Johnson KC, Swindell AC. 1996. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 13(12): 1795-1798.
4. Lipinski CA. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44(1):235-249.
5. Spahn-Langguth H, Baktir G, Radschuweit A, et al. 1998. P-Glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36(1): 16-24.
6. Yu DK. 1999. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39(12):1203-1211.
7. Chiou WL, Chung SM, Wu TC, Ma C. 2001. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 39(3):93-101.
8. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. 1999. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [see comments]. Circulation 99(4):552-557.
9. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. 2002. Drug interaction studies between paclitaxel (Taxol) and OC144-093-A new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 27(2):119-126.
10. Polli JW, Jarrett JL, Studenberg SD, et al. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16(8):1206-1212.
11. Peck RA, Hewett J, Harding MW, et al. 2001. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19(12):3130-3141.
12. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27(6):866-871.
13. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. 2000. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res 17(12):1456-1460.
14. Varga G, Kisfalvi K, Pelosini I, D'Amato M, Scarpignato C. 1998. Different actions of CCK on pancreatic and gastric growth in the rat: Effect of CCK(A) receptor blockade. Br J Pharmacol 124(3): 435-440.
15. Lentz KA, Hayashi J, Lucisano LJ, Polli JE. 2000. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. Int J Pharm 200(1):41-51.
16. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. 1992. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267(7):4854-4858.
17. Huai-Yun H, Secrest DT, Mark KS, et al. 1998. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 243(3):816-820.
18. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. 2001. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport. Cancer Res 61(19):7225-7232.
19. Adson A, Raub TJ, Burton PS, et al. 1994. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. J Pharm Sci 83(11):1529-1536.
20. Rege BD, Yu LX, Hussain AS, Polli JE. 2001. Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci 90(11):1776-1786.
21. Polli JE, Rekhi GS, Augsburger LL, Shah VP. 1997. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 86(6): 690-700.
22. Tsuji A, Takanaga H, Tamai I, Terasaki T. 1994. Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm Res 11(1):30-37.
23. Tang F, Horie K, Borchardt RT. 2002. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19(6):765-772.
24. Zhang Y, Benet LZ. 1998. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm Res 15(10):1520-1524.
25. Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, Benet LZ. 2002. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology 64(3):126-134.
26. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. 1996. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93(9):4001-4005.
27. Litman T, Druley TE, Stein WD, Bates SE. 2001. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58(7):931-959.
28. Wielinga PR, de Waal E, Westerhoff HV, Lankelma J. 1999. In vitro transepithelial drug transport by on-line measurement: Cellular control of paracellular and transcellular transport. J Pharm Sci 88(12):1340-1347.
29. Kruh GD, Gaughan KT, Godwin A, Chan A. 1995. Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst 87(16):1256-1258.
30. Persiani S, Damato M, Makovec F, Tavares IA, Bishai PM, Rovati LC. 2002. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int J Clin Pharmacol Ther 40(5):198-206.
31. Webber C, Roth A, Persiani S, et al. Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human volunteers. Xenobiotica 33(6):625-641.
32. Hall M, Cheung Y, Matthews A, et al. 2001. Phase I Metabolism of Dexloxiglumide (CR 2017) by Human Liver Microsomes. Drug Metab Rev 33(Suppl 1):91.
33. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
34. Tolle-Sander S, Polli JE. 2002. Method Considerations for Caco-2 Permeability Assessment in the Biopharmaceutics Classification System. Pharmacopeial Forum, Stimuli to the Revision Process 28(1):164-172.
35. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 46(1-3):3-26.
36. Katchen B, Symchowicz S. 1967. Correlation of dissolution rate and griseofulvin absorption in man. J Pharm Sci 56(9):1108-1111.
37. Dressman JB, Amidon GL, Fleisher D. 1985. Absorption potential: Estimating the fraction absorbed for orally administered compounds. J Pharm Sci 74(5):588-589.